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Pin1 specifically recognizes and catalyzes the cis-trans isomerization of phosphorylated-Ser/
Thr-Pro bonds, which modulate the stability, localization, and function of numerous Pin1
targets involved in tumor progression. However, the role of Pin1 in cancer remains enigmatic
as the gene is located on chromosome 19p13.2, which is a region subject to loss of heterozy-
gosity in several tumors. Since Pin1 protein is frequently under-expressed in kidney cancer,
we have explored its role in human clear cell renal cell carcinoma (ccRCC). Here we show
evidence for PIN1 gene deletion andmRNAunder-expression as amechanism of Pin1 reduc-
tion in ccRCC tumors. We demonstrate that restoration of Pin1 in cell lines found to be
deficient in Pin1 protein expression can attenuate the growth of ccRCC cells in soft agar
and a xenograft tumor model. Moreover, this ability of Pin1 to negatively influence tumor
growth in ccRCC cells may be dependent on the presence of functional p53, which is infre-
quentlymutated in ccRCC. These observations suggest Pin1mayhave amild tumor suppres-
sive role in ccRCC.
ª 2011 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction these targets are key regulators of G1-S progression, Pin1 hasPin1 is a conserved peptidyl-prolyl isomerase that specifically
recognizes phosphorylated serine/threonine-proline motifs
(pS/T-P) (Yaffeetal., 1997). Bycatalyzing the cis-trans isomeriza-
tion of pS/T-P bonds, Pin1 induces conformational changes in
its target phosphoproteins that can alter their biological func-
tion and/or stability (Lu and Zhou, 2007). Several proteins im-
portant for cell cycle and cancer progression are regulated by
Pin1, including b-catenin, c-Jun, c-Myc, cyclin D1, cyclin E,
and p53 (Liou et al., 2002; Ryo et al., 2001; Wulf et al., 2001;
Yehetal., 2004,2006;Zacchietal., 2002;Zhengetal., 2002). Sincearcinoma; MEF, mouse em
ontrol shRNA; shPin1, Pi
4; fax: þ1 919 966 8212.
W.K. Rathmell).
ation of European Biochebeen suggested to function as amolecular timer for the cell cy-
cle (Yeh and Means, 2007). Indeed, the loss of Pin1 in multiple
cell types, suchas Pin1/primordial germcells andmouseem-
bryonic fibroblasts (MEF), leads to prolongation of G0-G1-S pro-
gression (Atchison et al., 2003; Fujimori et al., 1999; You et al.,
2002). Such a delay could be explained by Pin1’s ability to pro-
mote the expression and stabilization of cyclin D1, underscor-
ing the potential importance of Pin1 in cancer.
A number of studies report prevalent Pin1 over-expression
in human cancers, including those of breast and prostate
(Ayala et al., 2003; Bao et al., 2004; Wulf et al., 2001). In breastbryonic fibroblasts; RPTEC, renal proximal tubule epithelial cells;
n1 shRNA.
mical Societies. Published by Elsevier B.V. All rights reserved.
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of cyclin D1, which is likely the result of enhanced transcrip-
tion of this gene by c-Jun and b-catenin as well as post-
translational stabilization of the protein (Ryo et al., 2001;
Wulf et al., 2001). Pin1 levels also correlate with poor clinical
outcome and may have prognostic value in the case of pros-
tate cancer (Ayala et al., 2003). Based on these studies, one
might conclude that increased levels of Pin1 promote tumor
progression. However, and perhaps not surprising given the
plethora of Pin1 targets, the role of Pin1 in human cancer is
complex and context dependent.
In fact, several reports suggest Pin1 might inhibit tumor
progression by destabilizing oncoproteins (i.e. cyclin E,
c-Myc) or by activating tumor suppressors (i.e. p53, p73) (Yeh
andMeans, 2007). Previously, we showed that cyclin E is stabi-
lized in Pin1/ C57BL6 MEF, which correlated with defective
cell cycle progression and accelerated genomic instability
(Yeh et al., 2006). Moreover, Pin1/ MEF cells transformed
with p53DD and/or H-RasG12V when grown as xenografts dis-
played reduced tumor free survival and increased tumor
growth compared to wild type MEF, which suggests Pin1
may exhibit a tumor suppressive effect in these cells. Since
Pin1 appears to play a tumor promoting or inhibitory role
depending on the genetic context, Pin1 has been described
as a “conditional” tumor suppressor (Yeh and Means, 2007).
However, Pin1-mediated tumor suppressive effects in a hu-
man context have yet to be demonstrated.
Interestingly, Pin1 is prevalently under-expressed in some
human cancers, including kidney cancer (Bao et al., 2004). Al-
though the relevance of Pin1 under-expression in kidney can-
cer has not been evaluated, the effect of differential Pin1 levels
on tumor progression likely depends on the specific repertoire
of genetic mutations acquired by the cancer cells. In particu-
lar, although p53 is commonly mutated in many human can-
cers, p53 mutation is infrequent in renal cell carcinoma (RCC)
(Dalgliesh et al., 2010; Gurova et al., 2004). Since Pin1 has been
shown to positively regulate p53, one hypothesis is that Pin1
can exert a tumor suppressive role in a manner dependent
on wild type p53. Herein, we evaluate the role of Pin1 in RCC
and find support for this hypothesis.2. Materials and methods
2.1. Copy number analysis
SNP6.0 array data corresponding to gene expression data de-
posited in Gene Expression Omnibus GSE17818 (Dalgliesh
et al., 2010) were obtained from theWellcome Trust Sanger In-
stitute (Hinxton, Cambridge, UK). Raw allele intensities were
imported into Partek Genomics Suite software, version 6.5
(St. Louis, MO, USA). Based on the PCA plot, one outlying
tumor and corresponding normal were excluded, batch effect
was removed, and copy number values were created from al-
lele intensities. Genomic segmentation was performed with
segmentation parameters of a minimum of 10 genomic
markers, p-value threshold of 0.001, and a signal to noise ratio
of 0.3. Identified regions were visualized using the Plot Chro-
mosome function within Partek Genomic Suite.2.2. Gene expression analysis
PIN1geneexpression levelswereexamined frompreviouslyde-
scribed gene expression data (Brannon et al., 2010), which was
re-downloaded with 44 additional new tumor samples from
the UNCMicroarray Database in log2 Lowess-normalized sam-
ple/reference format (median), filtered for 70% of probes pres-
ent above background levels and annotated using the
20101031 Agilent annotation release. The data was imported
into Partek Genomics Suite software and batch effect was
removed through Partek’s batch effect removal algorithms.
All human studies were approved by the University of North
Carolina Biomedical Institutional Review Board and Office of
Human Research Ethics.2.3. Cell lines and antibodies
Primary human renal proximal tubule epithelial cells (RPTEC)
were cultured in REGM Renal Epithelial Cell Growth Medium
(Lonza, Walkersville, MD, USA). Human renal cell carcinoma
ACHN and A498 cells, and human embryonic kidney 293T cells
(American Type Culture Collection, Manassas, VA, USA) were
cultured in Dulbecco’s modified Eagle’s medium (Mediatech,
Manassas,VA,USA) supplementedwith10% fetal bovineserum
(Gemini Bio-Products, West Sacramento, CA, USA) and 1%
penicillin-streptomycin (Mediatech). Cells were maintained at
37 Cina5%CO2humidifiedincubator.The followingantibodies
were used: anti-Pin1 (Winkler et al., 2000), anti-b-actin (Sigma-
eAldrich, St. Louis, MO, USA), anti-Ki67 (Lab Vision, Fremont,
CA, USA), IRDye800-conjugated anti-mouse IgG (Rockland Im-
munochemicals, Gilbertsville, PA, USA), and Alexa Fluor
680-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA).2.4. Retrovirus preparation and transduction
Pin1 shRNA construct was generated by inserting a sequence
targeting 50-CTGCCACCGTCACACAGTA-30 into pSUPER. Non-
silencing control shRNA construct pSUPER. Mamm-X was
obtained from Oligoengine (Seattle, WA, USA). Pin1 expres-
sion construct was created by PCR amplifying the human
Pin1 cDNA from pGEX-2TK-Pin1 (Yi et al., 2005) and ligating
it into the EcoRI-SalI sites of pBABE-neo. Site-directed muta-
genesis of pBABE-neo-Pin1WT to Pin1W34A was carried out by
GenScript (Piscataway, NJ, USA). pBABE-puro-p53DD construct
was created by excising p53DD from pBABE-hygro-p53DD (Yeh
et al., 2006), then inserting it into the BamHI-EcoRI sites of
pBABE-puro. Retroviruses were produced in 293T cells follow-
ing established methods (O’Hayer and Counter, 2006). ACHN
cells were infected with retrovirus, then stably selected using
1 mg/ml G418 (Invitrogen) or 2 mg/ml puromycin (Sigma-
eAldrich) for 7e10 days.2.5. Immunoblotting
Equal amounts of protein sample were resolved using
SDS-PAGE and then transferred to Immobilon-FL membrane
(Millipore, Billerica, MA, USA). Quantitative immunoblotting
was carried out using procedures established by LI-COR Bio-
sciences (Lincoln, NE, USA).
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RNA was isolated using RNeasy Plus Mini Kit (Qiagen, Valen-
cia, CA, USA). Transgenic expression of p53DD was verified
by RT-PCR as previously described (Adam and Counter, 2008).
2.7. Soft agar assay
Cellular transformation was evaluated by soft agar assay as
previously described (O’Hayer and Counter, 2006). Briefly,
2.5  104 ACHN cells were seeded per well of a 6-well plate.
Cells were fed with 0.2 ml of culture media every 3e4 days
for 21 days. Colonies greater than 30 cells were counted under
a light microscope. Images were acquired with a Sony DSC-
W50 (New York, NY, USA) attached to a Zeiss Axiovert 10 Mi-
croscope (Oberkochen, Germany) using a CamAdapter Kit
(The Microscope Store, Wirtz, VA, USA).
2.8. Xenograft tumor model
Five hundred thousand or 106 ACHN cells were subcutane-
ously injected into each flank of athymic nudemice using pro-
tocols approved by the University of North Carolina
Institutional Animal Care and Use Committee. Tumor dimen-
sionsweremeasured every 3e4 dayswith calipers until largest
tumors reached 0.8 cm in length, afterwhich the animalswere
sacrificed. Xenograft tumorswere fixedwith formalin and em-
bedded in paraffin for tissue sectioning.
2.9. Immunohistochemistry
Immunohistochemical staining was performed as previously
published (Chenet al., 2010). TUNELassaywasperformedusing
ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore).
High resolution images were captured using an Infinity 2-3
Camera (Lumenera Corporation, Ottawa, ON, Canada) affixed
to an Olympus CX41 Microscope (Center Valley, PA, USA). No
primary antibody control images are provided in
SupplementaryFigure3.AveragepercentDAB-positivestaining
was quantified from 10 different fields per tumor using Immu-
noRatio (Tuominenetal., 2010)orblindedmanual cell counting.
2.10. Statistical analysis
Bar graphs showmean standard error of the indicated num-
ber of experiments or samples. Statistical analyses were per-
formed using Microsoft Excel and StatView. Cutoff for
statistical significance was arbitrarily set at P < 0.05. * denotes
significant and ** denotes highly significant, with specific P
values indicated in the figure legends.3. Results
3.1. PIN1 gene is frequently deleted and under-expressed
in human clear cell RCC (ccRCC)
Previous studies indicate that the Pin1 protein is prevalently
under-expressed in kidney tumors compared to normal kid-
ney tissue (Bao et al., 2004). As shown in Figure 1A, wedetermined that Pin1 under-expression in kidney cancer
may be in part due to deletion of the PIN1 locus from chro-
mosome 19p13.2, and resultant haploinsufficiency, as copy
number analysis revealed Pin1 loss in 24 of 86 (28%) ccRCC tu-
mors. In order to evaluate the effective mRNA expression
level of the PIN1 gene, we examined 18 renal tumor and nor-
mal kidney paired samples for relative PIN1 gene expression.
We observed that the PIN1 gene was under-expressed in 4 of
18 (22%) ccRCC tumors relative to paired normal kidney tis-
sue (Figure 1B), which correlates with the frequency of PIN1
deletion observed in ccRCC. Since genetic loss of function is
a hallmark of tumor suppressors, we further assessed the rel-
evance of Pin1 under-expression in ccRCC by gene set analy-
sis (GSA). GSA revealed low Pin1 levels correlate with reduced
expression of genes involved in p53 stabilization as well as
mitotic cell cycle pathways (Supplementary Figure 1). In addi-
tion, depressed Pin1 levels are associated with increased ex-
pression of genes involved in metastasis, stem cell-related,
and proliferation pathways (Supplementary Figure 1). Collec-
tively, these observations are compatible with the hypothesis
that Pin1 may have tumor suppressive function in ccRCC.
3.2. Pin1 attenuates growth of ccRCC cells in soft agar
To test if Pin1 could serve a tumor suppressive role,we selected
two RCC cell lines that displayed reduced expression of Pin1
protein, ACHN and A498 (Figure 2A; Supplementary
Figure 2A). The rescue of reduced Pin1 levels to w1.5-fold nor-
mal levels with ectopic expression of Pin1 was sufficient to
modestly, but significantly inhibit the growth of both ACHN
and A498 cells in soft agar (Fig. 2AeC; Supplementary
Figure 2). Since A498 cells formed fewer andmuch smaller col-
onies, ACHN cells were chosen for further analysis of Pin1-
mediated effects. To evaluate the importance of Pin1’s WW-
domain in tumor suppressive activity, ACHN cells were trans-
ducedwith Pin1W34A, aWW-domainmutant incapable of bind-
ing toand isomerizingPin1 substrates (Luet al., 1999).Although
Pin1W34A was expressed at a level similar to Pin1WT (Figure 2A),
Pin1W34A was unable to diminish the growth of ACHN cells in
soft agar (Figure 2B, C). This result suggests a functional WW-
domain and canonical activity of Pin1 are essential for Pin1-
mediated inhibition of anchorage independent growth. Con-
versely to ectopic Pin1 expression, further Pin1 depletion
from ACHN cells by shRNA (Figure 2D) was associated with
a47%increase insoftagarcolonyformation (Figure2E,F).These
data demonstrate Pin1 can impede the growth of ccRCC cells in
soft agar, which is consistent with tumor suppressive activity.
3.3. Pin1 attenuates ACHN tumor growth in a xenograft
model
To further examine the role of Pin1 in tumor growth, ACHN-
Neo (vector control) and ACHN-Pin1 cells rescuedwith ectopic
Pin1 expressionwere assayed for tumorigenicity in a xenograft
model. Consistent with our soft agar assay data, Pin1 expres-
sion significantly improved tumor free survival and sup-
pressed the tumorigenic growth of ACHN xenografts
(Figure 3A, B). ACHN-Pin1 tumors were histologically similar
to ACHN-Neo control tumors, which exhibited necrotic cores
surrounded by proliferating cells (Figure 3C). In addition,
Figure 1 e PIN1 gene is frequently deleted and under-expressed in human ccRCC tumors. (A) Frequency of tumors containing deletion (blue) or
amplification (red) of each region of chromosome 19. The PIN1 gene on 19p13.2 (9945999.9960358) is highlighted in black. (B) Fold PIN1 gene
expression in individual ccRCC tumor samples relative to matched normal kidney tissue, as determined by gene expression microarray.
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mors retained elevated levels of Pin1 (Figure 3D), and thus
did not grow as a result of escaping Pin1 over-expression.
To explore themeans bywhich Pin1 expression impeded xe-
nograft growth, we compared rates of proliferation and apopto-
sis in the xenografts. Ectopic Pin1 expressing tumors displayed
significantly reducedKi67 staining, indicating that Pin1 contrib-
utes to decreased RCC tumor growth by inhibiting cellular pro-
liferation (Figure 4A). Indeed, ACHN-Pin1 tumors showed
a 29% decrease in the number of Ki67-positive nuclei
(Figure 4C), which is comparable to the impaired growth of
ACHN-Pin1 cells in soft agar (Figure 2C), and is consistent withour GSA showing that Pin1 negatively correlates with genes in-
volved in proliferation (Supplementary Figure 1). Intriguingly,
ectopic rescue of Pin1 also led to increased apoptosis in the xe-
nograft tumors as measured by TUNEL staining (Figure 4B, D).
Thus ectopic Pin1 expression attenuates ACHN tumor growth
through effects on both proliferation and apoptosis.
3.4. Repression of p53 activity can prevent Pin1-
mediated tumor inhibitory activity
Since previous research suggests Pin1 can enhance p53
function in order to inhibit cell proliferation and induce
Figure 2 e Pin1 attenuates growth of human renal cell carcinoma ACHN cells in soft agar. (A) RPTEC or ACHN cells transduced with empty
vector (Neo), Pin1 or Pin1W34A were analyzed by immunoblot. Average normalized Pin1 levels relative to RPTEC are below. (B, C) ACHN-Neo,
ACHN-Pin1, and ACHN-W34A cells were grown in soft agar. After 21 days, colonies were quantified from three independent assays done in
triplicate. (D) RPTEC or ACHN cells transduced with non-silencing control shRNA (NSC) or Pin1 shRNA (shPin1) were analyzed by
immunoblot as in (A). (E, F) ACHN-NSC and ACHN-shPin1 cells were assayed for growth in soft agar as in (B, C), except results represent two
independent experiments performed in triplicate. Scale bars represent 125 mm **P < 0.001 vs. control, t-test.
M O L E C U L A R O N C O L O G Y 5 ( 2 0 1 1 ) 4 6 5e4 7 4 469apoptosis in response to genotoxic stress (Zacchi et al., 2002;
Zheng et al., 2002), we hypothesized that the Pin1-mediated
growth inhibitory effect on tumors might require functional
p53, which is known to be wild type in ACHN cells
(O’Connor et al., 1997; Warburton et al., 2005). To test thishypothesis, p53 was specifically inhibited in ACHN-Pin1
cells by a dominant negative p53 (p53DD) mutant that we
have previously utilized (Yeh et al., 2006). Expression of
p53DD and Pin1 was verified by RT-PCR or immunoblot, re-
spectively (Figure 5A, B). As shown in Fig. 5CeE, as expected,
Figure 3 e Pin1 attenuates tumor growth of ACHN cells in xenograft model. ACHN-Neo and ACHN-Pin1 cells were subcutaneously injected
into each flank of athymic nude mice. (A) Tumor free survival of ACHN-Neo (n [ 8) and ACHN-Pin1 (n [ 8) xenografts was assessed by
KaplaneMeier survival analysis. P-value determined by log-rank test. (B) Tumor growth was assessed from measurements of tumor length.
P-value determined by repeated measures ANOVA. (C) Hematoxylin and eosin (H&E) staining. Scale bars represent 50 mm (D) Pin1 was detected
by DAB immunohistochemistry (IHC) then counterstained with hematoxylin. Scale bars represent 25 mm.
M O L E C U L A R O N C O L O G Y 5 ( 2 0 1 1 ) 4 6 5e4 7 4470the inhibition of p53 by p53DD enhanced growth in soft agar
and in xenograft; however, ectopic Pin1 rescue in this set-
ting failed to suppress soft agar colony formation or xeno-
graft tumor growth. Therefore Pin1-mediated tumor
inhibitory activity in RCC appears to require functional p53.4. Discussion
Here we provide the first demonstration of Pin1-mediated tu-
mor inhibitory activity in human cancer cells. The restoration
of Pin1 expression in Pin1-deficient ccRCC cells produced re-
ductions in tumor cell growth in soft agar, as well as inxenograft model growth. These effects although modest,
were significant, and would be expected to have substantial
consequences over the long natural history of renal cell carci-
noma. Because tumorigenicity was not ablated, we have re-
ferred to Pin1 as a protein with tumor inhibitory activity,
rather than a nascent tumor suppressor. Moreover, Pin1’s tu-
mor inhibitory effects in renal carcinoma cells seem to require
functional p53, as p53 inhibition was sufficient to prevent
Pin1-mediated tumor suppressive activity in these cells. This
result suggests the possibility that Pin1 acts to attenuate tu-
mor cell growth in conditions in which p53 signaling is intact,
and is consistent with the physiologic role of Pin1 in positively
regulating p53 biological function, which has been previously
Figure 4 e Pin1 attenuates ACHN xenograft tumor growth through effects on proliferation and apoptosis. (A) Proliferation was assessed by IHC
analysis of Ki67. (B) Apoptosis was evaluated by TUNEL assay. Black arrows point to examples of DAB-positive nuclei. (C, D) Average percent
DAB-positive nuclei was quantified for (A) Ki67 and (B) TUNEL stains respectively. Data represent ACHN-Neo (n [ 8) and ACHN-Pin1
(n [ 7) with *P < 0.05 vs. control, t-test. Scale bars represent 25 mm.
M O L E C U L A R O N C O L O G Y 5 ( 2 0 1 1 ) 4 6 5e4 7 4 471documented (Berger et al., 2005; Mantovani et al., 2007; Zacchi
et al., 2002; Zheng et al., 2002). As the PIN1 gene is frequently
deleted in ccRCC tumors and Pin1 exhibits tumor attenuating
activity in p53 wild type ccRCC cell lines, but not those in
which p53 is inhibited, we surmise that Pin1 may play an im-
portant role in cancer biology to conditionally inhibit growth
in some scenarios while exerting tumor promoting activities
in other contexts.
Certainly, the concept of a protein functioning with condi-
tional tumor suppressive activity is not novel. Indeed, there
are several proteins reported to possess tumor suppressing
or promoting activity depending on the genetic context, in-
cluding deleted in colon cancer (DCC), netrin-1 and transform-
ing growth factor b (TGFb) (Massague, 2008; Mazelin et al.,2004). In “normal” contexts, TGFb mediates tumor suppres-
sion through mechanisms that regulate cytostasis, apoptosis,
and differentiation. However, TGFb can alternatively promote
the growth and metastasis of tumors containing certain ge-
netic mutations or deletions that disable TGFb’s tumor sup-
pressive function. The example of TGFb interestingly seems
to share some parallels with what has been observed for
Pin1 in cancer. Since Pin1 has been shown to function to either
decrease or enhance tumor growth, we speculate that muta-
tions that disable Pin1’s tumor suppressing activities (i.e. p53
mutation) may enhance Pin1’s tumor promoting activities
(i.e. cyclin D1 over-expression) in these contexts. Notably, fre-
quent Pin1 over-expression correlatingwith high cyclin D1 ex-
pression has been shown to occur in human cancers where
Figure 5 e Repression of p53 blocks Pin1-mediated tumor suppressive activity in ACHN cells. (A) ACHN cells transduced with the indicated
combinations of vector (Neo, Puro), Pin1, and p53DD were analyzed for p53DD expression by RT-PCR. (B) Ectopic Pin1 expression in cell lines
from (A) was confirmed by immunoblot. (C, D) ACHN cells from (A, B) were assayed for growth in soft agar with results quantified from two
independent experiments performed in triplicate. Scale bars represent 125 mm. (E) Final tumor length of ACHN xenograft tumors (n [ 8) grown
for four months. *P < 0.05 or **P < 0.005 vs. corresponding Neo control, t-test.
M O L E C U L A R O N C O L O G Y 5 ( 2 0 1 1 ) 4 6 5e4 7 4472p53 is frequently mutated, including breast and liver cancers
(Pang et al., 2004; Wulf et al., 2001).
On the other hand, frequent Pin1 under-expression has
been most commonly observed in cancers where p53 is fre-
quently wild type, including kidney and testicular cancers
(Bao et al., 2004; Gurova et al., 2004; Heimdal et al., 1993). Based
on theseobservations, the role of Pin1 as an inhibitor of human
tumorigenesis seems to be highly dependent on the tumor cell
context. In ccRCC which harbors infrequent mutations of p53and other common mediators of tumorigenesis, Pin1 appears
to play a mild tumor suppressive role, and further investiga-
tion iswarranted to ascertain if Pin1 could be a useful prognos-
tic factor or therapeutic target in human cancer.Conflict of interest
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